title: In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection.
abstract: The aim of this work was to determine the in vitro activity of tigecycline and its bactericidal effect for a large number of Gram-positive cocci, as well as to investigate its in vitro interaction with six clinically used antibiotics. In vivo, a wound model was established through the panniculus carnosus of BALB/c mice, and then inoculated with 5 × 10(7) colony-forming units (CFU) of Staphylococcus aureus or Enterococcus faecalis. For each bacterial strain, the study included an infected or non-infected group that did not receive any treatment, three groups singly treated with tigecycline, rifampin, and daptomycin, and two groups that received tigecycline treatment plus rifampin or daptomycin. In the in vitro studies, tigecycline, daptomycin, and teicoplanin were active against all of the 48 Gram-positive isolates. The combination of tigecycline with rifampicin and daptomycin was synergistic against S. aureus and Enterococcus spp. In the in vivo studies, all groups treated with single drugs showed statistically significant results compared to the control group. The two groups treated with a combination of drugs showed the highest antimicrobial efficacy. In conclusion, our results suggested a strong activity of tigecycline alone and in combination with other antimicrobial agents against multi-resistant Gram-positive organisms isolated from wound infections.
authors.affiliation: Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche-Ospedali Riuniti, Ancona, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Silvestri
authors.forename: O
authors.initials: O
authors.lastname: Cirioni
authors.forename: D
authors.initials: D
authors.lastname: Arzeni
authors.forename: R
authors.initials: R
authors.lastname: Ghiselli
authors.forename: O
authors.initials: O
authors.lastname: Simonetti
authors.forename: F
authors.initials: F
authors.lastname: Orlando
authors.forename: G
authors.initials: G
authors.lastname: Ganzetti
authors.forename: S
authors.initials: S
authors.lastname: Staffolani
authors.forename: L
authors.initials: L
authors.lastname: Brescini
authors.forename: M
authors.initials: M
authors.lastname: Provinciali
authors.forename: A
authors.initials: A
authors.lastname: Offidani
authors.forename: M
authors.initials: M
authors.lastname: Guerrieri
authors.forename: A
authors.initials: A
authors.lastname: Giacometti
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D017576:Daptomycin / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology*; D006095:Gram-Positive Cocci / Q000187:drug effects* / Q000302:isolation & purification; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology*; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000382:microbiology*; D000078304:Tigecycline; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline; D017576:Daptomycin; D012293:Rifampin